PIK75

• CAT Number: I003369
• CAS Number: 372196-77-5
• Molecular Formula: C₁₆H₁₅BrClN₅O₄S
• Molecular Weight: 488.74
• Purity: ≥95%
• Synonyms: N-[(E)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-N,2-dimethyl-5-nitrobenzenesulfonamide;hydrochloride
• Target: PI3K
• Solubility: DMSO ≥16mg/mL Water <1.2mg/mL Ethanol ≥4.6mg/mL
• Storage: 3 years -20C powder
• IC50: 5.8/2 nM(p110α/DNA-PK)

PIK75（Cat No.:I003369）is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K), particularly targeting the p110α isoform of PI3K. By inhibiting PI3K activity, PIK75 blocks the PI3K/AKT signaling pathway, which is critical for cell growth, survival, and proliferation. This compound has shown significant anti-cancer activity by inducing apoptosis and inhibiting tumor cell proliferation, especially in cancers with PI3K pathway mutations. PIK75 is widely used in cancer research to study PI3K-driven oncogenesis and to explore potential therapeutic strategies for targeting aberrant PI3K/AKT signaling in various cancers.

Reference

[1]. Zheng Z, et al. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition. Mol Pharmacol. 2011, 80(4), 657-664.
[2]. WO/2003/072557, 09/04/2003
[3]. Moir LM, et al. Phosphatidylinositol 3-kinase isoform-specific effects in airway mesenchymal cell function. J Pharmacol Exp Ther. 2011, 337(2), 557-566.
[4]. Smirnova T, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012, 31(6), 706-715.
[5]. Smith GC, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J. 2012, 442(1), 161-169.